| References: |
Dacomitinib is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of PF-299804 (Dacomitinib, PF-00299804) in water, the solubility of PF-299804 (Dacomitinib, PF-00299804) in DMSO, the solubility of PF-299804 (Dacomitinib, PF-00299804) in PBS buffer, the animal experiment（test） of PF-299804 (Dacomitinib, PF-00299804),the in vivo,in vitro and clinical trial test of PF-299804 (Dacomitinib, PF-00299804),the cell experiment（test） of PF-299804 (Dacomitinib, PF-00299804),the IC50, EC50 and Affinity of PF-299804 (Dacomitinib, PF-00299804), please contact DC Chemicals. |
